

Scott M Wasserman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7484611/publications.pdf>

Version: 2024-02-01

9
papers

5,660
citations

1307594

7
h-index

1588992

8
g-index

9
all docs

9
docs citations

9
times ranked

6794
citing authors

#	ARTICLE	IF	CITATIONS
1	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 376, 1713-1722.	27.0	4,179
2	Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 2373.	7.4	813
3	Cognitive Function in a Randomized Trial of Evolocumab. <i>New England Journal of Medicine</i> , 2017, 377, 633-643.	27.0	366
4	Effect of Evolocumab on Coronary Plaque Composition. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2012-2021.	2.8	95
5	Effects of Evolocumab on Vitamin E and Steroid Hormone Levels. <i>Circulation Research</i> , 2015, 117, 731-741.	4.5	80
6	Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism. <i>Circulation</i> , 2017, 135, 338-351.	1.6	80
7	Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV). <i>American Heart Journal</i> , 2016, 176, 83-92.	2.7	45
8	C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV. <i>American Journal of Preventive Cardiology</i> , 2020, 3, 100091.	3.0	2
9	Response by Watts et al to Letter Regarding Article, "Factorial Effects of Evolocumab and Atorvastatin on Lipoprotein Metabolism". <i>Circulation</i> , 2017, 136, 120-121.	1.6	0